Background
Phase II RCT. 49 patients with stage IV NSCLC and ≤3 metastatic sites who had not progressed after first-line systemic therapy (chemotherapy or targeted therapy). Randomized to local consolidative therapy (LCT: SBRT, surgery, or chemoradiation to all disease sites) vs maintenance therapy or observation alone. First randomized trial of LCT for oligometastatic NSCLC.
Interventions and follow up
Arm A: Local consolidative therapy (SBRT, SABR, or surgery) to all sites of disease ± concurrent systemic therapy — 25 patient
Arm B: Maintenance therapy (erlotinib, bevacizumab, pemetrexed, or observation) — 24 patient
Primary endpoint: PFS
mFollow up: 38.8 months (long-term update)
Arm B: Maintenance therapy (erlotinib, bevacizumab, pemetrexed, or observation) — 24 patient
Primary endpoint: PFS
mFollow up: 38.8 months (long-term update)
Results
mPFS (LCT): 14.2 months vs maintenance 4.4 months, HR 0.35, P=.0076
mOS (LCT): 41.2 months vs maintenance 17.0 months, HR 0.37, P=.017
Time to new metastasis: 23.1 vs 6.2 months — significant delay
mOS (LCT): 41.2 months vs maintenance 17.0 months, HR 0.37, P=.017
Time to new metastasis: 23.1 vs 6.2 months — significant delay
Adverse events
Main adverse events: LCT arm: grade ≥3 adverse events 6 patients (esophagitis 2, pulmonary toxicity 2, vertebral fracture 1). No grade ≥3 in maintenance arm. No treatment-related deaths.
Conclusions
LCT significantly improved both PFS and OS in oligometastatic NSCLC patients with controlled disease after first-line systemic therapy, representing the strongest randomized evidence for LCT in this setting. The OS benefit (41 vs 17 months) is clinically profound though the trial was small and underpowered.
Key Limitations
Key Limitations: Small sample size (49 patients) — underpowered; trial stopped early for benefit. Heterogeneous LCT approaches (SBRT, surgery, CRT) make it difficult to attribute benefit to specific technique. Systemic therapy was variable across patients. Molecular profiling (EGFR, ALK status) not balanced in updated report. May not apply to immunotherapy era patients.
Clinical Context
The Gomez trial (with the NRG LU002 and MDACC oligometastatic NSCLC trials) supports LCT for oligometastatic NSCLC with ≤3 sites of controlled disease. Current NCCN guidelines include this as a recommended option. Confirmatory phase III trials (NRG-LU002) are ongoing. Timing relative to systemic therapy (especially immunotherapy + chemo) is under active investigation.
References